Clinical relevance of autoantibody detection in lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 955-962

  Solassol, Jerome ^a,b   Maudelonde, Thierry ^a,b   Mange, Alain ^a,b   Pujol, Jean Louis ^a,b  

^a UNIV MONTPELLIER   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Autoantibody; Immune response; Lung cancer; Screening

Indexed keywords

3 OXOACID COENZYME A TRANSFERASE; ALDEHYDE DEHYDROGENASE; ALPHA ENOLASE; AUTOANTIBODY; CHAPERONIN; COMPLEMENT FACTOR H; COMPLEMENTARY DNA; CYTOKERATIN 18; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FK 506 BINDING PROTEIN; GENE PRODUCT; HEAT SHOCK PROTEIN; INOSINATE DEHYDROGENASE; LIPOCORTIN 1; LIPOCORTIN 2; LIVIN; MELANOMA ANTIGEN 3; MUCIN 1; NY ESO 1 ANTIGEN; PEROXIREDOXIN 1; PEROXIREDOXIN 6; PROTEIN P53; SURVIVIN; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX3;

ADAPTIVE IMMUNITY; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; APOPTOSIS; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOGENESIS; CELLULAR IMMUNITY; GENETIC ASSOCIATION; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNODETECTION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG CANCER; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MICROARRAY; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR PROMOTION;

EID: 79955469016     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318215a0a4     Document Type: Article

References (103)

1. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245-258. (Pubitemid 36970181)
2. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-573.
3. Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008;3:781-792.
4. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:740-753.
5. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
6. Muley T, Dienemann H, Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 2004;24:1953-1956. (Pubitemid 38954616)
7. Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004;126:114-121. (Pubitemid 38943126)
8. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771. (Pubitemid 44631359)
9. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med 2005;352:2714-2720. (Pubitemid 41007826)
10. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-5066.
11. Jorgensen LG, Hansen HH, Cooper EH. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol 1989;25:123-128. (Pubitemid 19030252)
12. Pujol JL, Grenier J, Daures JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-66. (Pubitemid 23019377)
13. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004;90:2097-2105. (Pubitemid 38869712)
14. Chakra M, Pujol JL, Lamy PJ, et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008;3:1119-1126.
15. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in nonsmall cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
16. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006;42:1-41. (Pubitemid 44302105)
17. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
18. Stebbing J, Duru O, Bower M. Non-AIDS-defining cancers. Curr Opin Infect Dis 2009;22:7-10.
19. Aractingi S, Kanitakis J, Euvrard S, et al. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res 2005;65:1755-1760. (Pubitemid 40478601)
20. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111. (Pubitemid 32391043)
21. Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008; 84:981-987.
22. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998. (Pubitemid 35363648)
23. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360. (Pubitemid 38680426)
24. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907. (Pubitemid 350231320)
25. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007;19:203-208. (Pubitemid 46356963)
26. Willimsky G, Blankenstein T. The adaptive immune response to sporadic cancer. Immunol Rev 2007;220:102-112. (Pubitemid 350045578)
27. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-146. (Pubitemid 41613441)
28. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-423. (Pubitemid 40719125)
29. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003;52:715-738. (Pubitemid 37491701)
30. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-3442.
31. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-3803. (Pubitemid 32057286)
32. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-702.
33. Desmetz C, Bascoul-Mollevi C, Rochaix P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009;15:4733-4741.
34. Hanisch FG, Ninkovic T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr Protein Pept Sci 2006;7:307-315.
35. Tomkiel JE, Alansari H, Tang N, et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res 2002;8:752-758. (Pubitemid 34742104)
36. Disis ML, Knutson KL, Schiffman K, et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62: 245-252.
37. Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu proteinspecific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-3367. (Pubitemid 27485856)
38. Lenner P, Wiklund F, Emdin SO, et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a populationbased epidemiological study. Br J Cancer 1999;79:927-932. (Pubitemid 29082128)
39. Gumus E, Erdamar S, Demirel G, et al. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004;11:1070-1077. (Pubitemid 40053006)
40. Canevari S, Pupa SM, Menard S. 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 1996;7:227-232.
41. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-11813. (Pubitemid 26014201)
42. Li G, Miles A, Line A, et al. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53:139-143. (Pubitemid 38328034)
43. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008;63:228-233. (Pubitemid 351373718)
44. Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007;360: 319-326.
45. Kim MS, Choi HY, Choi YS, et al. Optimized serological isolation of lung-cancer-associated antigens from a yeast surface-expressed cDNA library. J Microbiol Biotechnol 2007;17:993-1001. (Pubitemid 47162064)
46. Wadle A, Mischo A, Imig J, et al. Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer 2005;117:104-113. (Pubitemid 41262764)
47. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001;1:890-898. (Pubitemid 33587414)
48. Desmetz C, Bibeau F, Boissiere F, et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res 2008;7:3830-3837.
49. Cui JW, Li WH, Wang J, et al. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 2005;4:1718-1724. (Pubitemid 41749265)
50. Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:6415-6420. (Pubitemid 44799713)
51. Suzuki A, Iizuka A, Komiyama M, et al. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010;7:17-23.
52. Ekins R. A shadow over immunoassay. Nature 1989;340:256-258.
53. Fodor SP, Read JL, Pirrung MC, et al. Light-directed, spatially addressable parallel chemical synthesis. Science 1991;251:767-773. (Pubitemid 21926165)
54. Feng Y, Ke X, Ma R, et al. Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 2004;50:416-422. (Pubitemid 38156384)
55. Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 2007;104:17494-17499. (Pubitemid 350219866)
56. Gnjatic S, Ritter E, Buchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 2010;107:5088-5093.
57. Ehrlich JR, Tang L, Caiazzo RJ Jr, et al. The "reverse capture" autoantibody microarray: an innovative approach to profiling the autoantibody response to tissue-derived native antigens. Methods Mol Biol 2008;441:175-192.
58. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-1235. (Pubitemid 41345944)
59. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261-267. (Pubitemid 38500993)
60. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003;3:2108-2115. (Pubitemid 37414076)
61. Gure AO, Stockert E, Scanlan MJ, et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci USA 2000;97:4198-4203. (Pubitemid 30226110)
62. Brichory F, Beer D, Le Naour F, et al. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001;61:7908-7912. (Pubitemid 33049381)
63. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001;98:9824-9829. (Pubitemid 32769388)
64. Sangrajrang S, Sornprom A, Chernrungroj G, et al. Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 2003;39:297-301. (Pubitemid 36284730)
65. Li Y, Karjalainen A, Koskinen H, et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005;114:157-160. (Pubitemid 40194322)
66. Tureci O, Mack U, Luxemburger U, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006;236:64-71.
67. Yagihashi A, Asanuma K, Kobayashi D, et al. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 2005;48:217-221.
68. Nakanishi T, Takeuchi T, Ueda K, et al. Detection of eight antibodies in cancer patients' sera against proteins derived from the adenocarcinoma A549 cell line using proteomics-based analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2006;838:15-20. (Pubitemid 43832210)
69. Chang JW, Lee SH, Jeong JY, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005;579:2873-2877.
70. Yang F, Xiao ZQ, Zhang XZ, et al. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007;6:751-758. (Pubitemid 46340178)
71. He P, Naka T, Serada S, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 2007;98:1234-1240. (Pubitemid 46993544)
72. Amornsiripanitch N, Hong S, Campa MJ, et al. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010;16:3226-3231.
73. Nagashio R, Sato Y, Jiang SX, et al. Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 2008;62:364-373.
74. Yao X, Jiang H, Zhang C, et al. Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer. Biomarkers 2010;15:128-134.
75. Zhang XZ, Xiao ZF, Li C, et al. Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. Cancer Sci 2009;100:2396-2401.
76. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-1788. (Pubitemid 30207629)
77. Li Y, Brandt-Rauf PW, Carney C, et al. Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers 1999;4:381-390. (Pubitemid 29482963)
78. Trivers GE, De Benedetti VM, Cawley HL, et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-1775. (Pubitemid 26356363)
79. Vural B, Chen LC, Saip P, et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 2005; 103:2575-2583. (Pubitemid 40800537)
80. Maddison P, Thorpe A, Silcocks P, et al. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 2010;70:335-339.
81. Bylund M, Andersson E, Novitch BG, et al. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 2003;6:1162-1168. (Pubitemid 37346036)
82. Sandberg M, Kallstrom M, Muhr J. Sox21 promotes the progression of vertebrate neurogenesis. Nat Neurosci 2005;8:995-1001. (Pubitemid 41061509)
83. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009;27:4260-4267.
84. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479. (Pubitemid 28411135)
85. Lim LH, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 2007;21:968-975. (Pubitemid 46495688)
86. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007;13:3568-3575. (Pubitemid 350238927)
87. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918. (Pubitemid 27113936)
88. Chen G, Wang X, Yu J, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007;67:3461-3467. (Pubitemid 46724887)
89. Pereira-Faca SR, Kuick R, Puravs E, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res 2007;67:12000-12006.
90. Khattar NH, Coe-Atkinson SP, Stromberg AJ, et al. Lung cancerassociated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer. Cancer Biol Ther 2010;10: 267-272.
91. Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res 2010;16:3760-3768.
92. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011;22:383-389.
93. Winter SF, Sekido Y, Minna JD, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-2018. (Pubitemid 24000985)
94. Lai CL, Tsai CM, Tsai TT, et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 1998;4:3025-3030.
95. Rosenfeld MR, Malats N, Schramm L, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997;89:381-385. (Pubitemid 27102603)
96. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-8062. (Pubitemid 41698748)
97. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000;161:589-594. (Pubitemid 30129471)
98. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008;3:S164-S170. (Pubitemid 351786751)
99. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13:s4652-s4654.
100. Vansteenkiste J, Zielinski M, Linder A. Final results of a multi-center, doubleblind, randomized, placebo controlled Phase II study to assess the efficacy of MAGEA3. immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(Suppl):(abstract 7554).
101. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-374.
102. Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49 -57; discussion 58. (Pubitemid 32904315)
103. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681. (Pubitemid 46190262)